---
schema_version: "secwatch.filing_event.v1"
accession: "0001753926-25-000035"
form_type: "8-K"
ticker: "LIPO"
cik: "0001347242"
company_name: "LIPELLA PHARMACEUTICALS INC."
filed_at: "2025-01-06T23:59:59+00:00"
generated_at: "2026-05-28T09:58:54.663867+00:00"
event_type: "debt"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Lipella raises $368K in second closing of Series B preferred offering; CEO gets voting proxy

## Summary
- Second closing issued 3,680 shares of Series B non-voting convertible preferred at $100/share, convertible into 117,948 common shares at $3.12/share.
- Net proceeds of $305,440; use for working capital and general corporate purposes.
- Placement agent Spartan received $62,560 in fees, 42,933 Series C voting preferred shares, and a warrant for 11,795 common shares.
- Spartan granted CEO Jonathan Kaufman irrevocable voting power over all Series C and warrant shares via proxy agreement.
- Total offering remains open up to $6.0 million; first closing on Dec 30 sold 22,295 Series B shares for $2.23M.

## SEC filing metadata
- accession: 0001753926-25-000035
- form_type: 8-K
- ticker: LIPO
- cik: 0001347242
- company_name: LIPELLA PHARMACEUTICALS INC.
- filed_at: 2025-01-06T23:59:59+00:00
- event_type: debt
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1347242/000175392625000035/0001753926-25-000035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1347242/000175392625000035/g084643_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001753926-25-000035
- JSON: https://secwatch.observer/filing/0001753926-25-000035.json
- Plain text: https://secwatch.observer/filing/0001753926-25-000035.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.